NO20040731L - Medisinsk bruk av histon-deacetylase inhibitor og fremgangsmate og evaluering av dens antitumor-virkning. - Google Patents

Medisinsk bruk av histon-deacetylase inhibitor og fremgangsmate og evaluering av dens antitumor-virkning.

Info

Publication number
NO20040731L
NO20040731L NO20040731A NO20040731A NO20040731L NO 20040731 L NO20040731 L NO 20040731L NO 20040731 A NO20040731 A NO 20040731A NO 20040731 A NO20040731 A NO 20040731A NO 20040731 L NO20040731 L NO 20040731L
Authority
NO
Norway
Prior art keywords
antitumor effect
histone deacetylase
evaluation
deacetylase inhibitor
inhibitor
Prior art date
Application number
NO20040731A
Other languages
English (en)
Other versions
NO331682B1 (no
Inventor
Yuka Sasakawa
Yoshinori Naoe
Original Assignee
Fujisawa Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co filed Critical Fujisawa Pharmaceutical Co
Publication of NO20040731L publication Critical patent/NO20040731L/no
Publication of NO331682B1 publication Critical patent/NO331682B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

Terapeutisk middel for prostatacancer og malignt lymfom inneholdende FK228 eller et salt derav som en aktiv ingrediens, og en fremgangsmåte for å evaluere en antitumoreffekt av en histondeacetylase-inhibitor som inkluderer minst ett trinn for å behandle en testcelle med en histondeacetylace-inhibitor, et trinn for å måle forandring i ekspresjonsmengden av et spesifikt gen i testcellen før og etter behandlingen med inhibitoren, og sammenligne begge ekspresjonsmengder.
NO20040731A 2001-08-21 2004-02-20 Medisinsk anvendelse av histon-deacetylase inhibitor. NO331682B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2001250846 2001-08-21
PCT/JP2002/008355 WO2003015810A1 (fr) 2001-08-21 2002-08-20 Usage medical d'un inhibiteur d'histone desacetylase et methode d'evaluation de son activite antitumorale

Publications (2)

Publication Number Publication Date
NO20040731L true NO20040731L (no) 2004-04-20
NO331682B1 NO331682B1 (no) 2012-02-20

Family

ID=19079582

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040731A NO331682B1 (no) 2001-08-21 2004-02-20 Medisinsk anvendelse av histon-deacetylase inhibitor.

Country Status (14)

Country Link
US (1) US8470783B2 (no)
EP (1) EP1426054B1 (no)
JP (1) JP4238728B2 (no)
AT (1) ATE526029T1 (no)
CA (1) CA2457043A1 (no)
DK (1) DK1426054T3 (no)
ES (1) ES2371630T3 (no)
HU (1) HU229521B1 (no)
MX (1) MXPA04001612A (no)
NO (1) NO331682B1 (no)
PL (1) PL210794B1 (no)
PT (1) PT1426054E (no)
RU (1) RU2298414C2 (no)
WO (1) WO2003015810A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005521737A (ja) * 2002-04-05 2005-07-21 藤沢薬品工業株式会社 腎臓癌の治療のためのデプシペプチド
KR20050106438A (ko) * 2003-02-19 2005-11-09 아스텔라스세이야쿠 가부시키가이샤 히스톤 디아세틸라제 저해제의 항종양 효과의 예측방법
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
DK2263694T3 (da) * 2003-09-25 2013-08-26 Astellas Pharma Inc Antitumormiddel omfattende histon-deacetylase-inhibitoren FK228 og topoisomerase-II-inhibitoren doxorubicin
EP1713460A2 (en) * 2003-12-10 2006-10-25 Wisconsin Alumni Research Foundation Fk228 analogs and their use as hdac-inhibitors
WO2005059167A1 (en) * 2003-12-18 2005-06-30 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Method for identifying histone deacetylase inhibitors
US20050187148A1 (en) * 2004-02-25 2005-08-25 Yoshinori Naoe Antitumor agent
US7951780B2 (en) 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent
KR101167601B1 (ko) * 2004-02-25 2012-07-27 아스텔라스세이야쿠 가부시키가이샤 항종양제
JP2006000113A (ja) * 2004-05-20 2006-01-05 Masatomo Sakurai 漢方医療の診断に用いる遺伝子およびその利用方法
EP2522395A1 (en) 2005-02-03 2012-11-14 TopoTarget UK Limited Combination therapies using HDAC inhibitors
WO2006094068A2 (en) 2005-03-01 2006-09-08 The Regents Of The University Of Michigan Hdac inhibitors that promote brm expression and brm related diagnostics
DK2494969T3 (en) 2005-05-13 2015-06-15 Topotarget Uk Ltd Pharmaceutical formulations of the HDAC inhibitors
KR20080032188A (ko) 2005-07-14 2008-04-14 다케다 샌디에고, 인코포레이티드 히스톤 탈아세틸화 효소 억제제
WO2007024574A2 (en) * 2005-08-19 2007-03-01 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Topical formulations of histone deacetylase inhibitors and methods of using the same
AU2006313517B2 (en) 2005-11-10 2013-06-27 Topotarget Uk Limited Histone deacetylase (HDAC) inhibitors (PXD101) for the treatment of cancer alone or in combination with chemotherapeutic agent
US20070129290A1 (en) * 2005-11-18 2007-06-07 Or Yat S Metabolite derivatives of the HDAC inhibitor FK228
WO2007145704A2 (en) * 2006-04-24 2007-12-21 Gloucester Pharmaceuticals Gemcitabine combination therapy
US8957027B2 (en) * 2006-06-08 2015-02-17 Celgene Corporation Deacetylase inhibitor therapy
ES2529147T3 (es) 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
CN101687010A (zh) * 2006-12-29 2010-03-31 格洛斯特制药公司 制备Romidepsin
CA2674309A1 (en) * 2006-12-29 2008-07-10 Gloucester Pharmaceuticals, Inc. Preparation of romidepsin
NZ579048A (en) 2007-01-30 2012-05-25 Pharmacyclics Inc Methods for determining cancer resistance to histone deacetylase inhibitors
MX2010003230A (es) 2007-09-25 2010-04-07 Topotarget Uk Ltd Metodos para la sintesis de ciertos compuestos de acido hidroxamico.
SG187032A1 (en) * 2010-07-12 2013-02-28 Celgene Corp Romidepsin solid forms and uses thereof
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
CN103917231B (zh) 2011-09-13 2016-09-28 药品循环有限责任公司 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8817743D0 (en) * 1988-07-26 1988-09-01 Fujisawa Pharmaceutical Co Fr901228 substance & preparation thereof
US6030961A (en) 1997-03-11 2000-02-29 Bar-Ilan Research & Development Co., Ltd. Oxyalkylene phosphate compounds and uses thereof
AU732299B2 (en) 1997-09-02 2001-04-12 Japan Energy Corporation Novel cyclic tetrapeptide derivatives and pharmaceutical use thereof
CA2308565A1 (en) * 1997-11-05 1999-05-14 Baylor College Of Medicine Sequences for targeting metastatic cells
JPH11335375A (ja) 1998-05-20 1999-12-07 Mitsui Chem Inc ヒストン脱アセチル化酵素阻害作用を有するベンズアミド誘導体
JP2003509343A (ja) 1999-09-08 2003-03-11 スローン−ケターリング インスティチュート フォー キャンサー リサーチ 新規クラスの細胞分化剤およびヒストンデアセチラーゼならびにそれらの使用方法
PT1438966E (pt) 1999-12-08 2007-05-31 Cyclacel Pharmaceuticals Inc Uso de depsipéptidos e seus congéneres como imunosupressores para tratamento de doenças infecciosas, como uma doença autoimune, reacções alérgicas ou doença hiperproliferativa da pele.
CA2317003A1 (en) * 2000-02-28 2001-08-28 Hidenori Nakajima Gene expression potentiator
JP2001348340A (ja) * 2000-06-07 2001-12-18 Yamanouchi Pharmaceut Co Ltd ヒストン脱アセチル化酵素阻害剤
ATE425177T1 (de) * 2000-07-17 2009-03-15 Astellas Pharma Inc Reduziertes fk228 und seine verwendung
JP2005521737A (ja) * 2002-04-05 2005-07-21 藤沢薬品工業株式会社 腎臓癌の治療のためのデプシペプチド
EP1638541B1 (en) * 2003-06-27 2010-05-19 Astellas Pharma Inc. Therapeutic agent for soft tissue sarcoma
DK2263694T3 (da) * 2003-09-25 2013-08-26 Astellas Pharma Inc Antitumormiddel omfattende histon-deacetylase-inhibitoren FK228 og topoisomerase-II-inhibitoren doxorubicin
US7951780B2 (en) * 2004-02-25 2011-05-31 Astellas Pharma Inc. Antitumor agent

Also Published As

Publication number Publication date
ATE526029T1 (de) 2011-10-15
RU2004108137A (ru) 2005-05-10
EP1426054A1 (en) 2004-06-09
PL210794B1 (pl) 2012-03-30
HUP0400668A3 (en) 2012-09-28
HUP0400668A2 (hu) 2005-01-28
WO2003015810A1 (fr) 2003-02-27
JP4238728B2 (ja) 2009-03-18
EP1426054A4 (en) 2006-09-13
US20050191713A1 (en) 2005-09-01
DK1426054T3 (da) 2011-12-12
CA2457043A1 (en) 2003-02-27
RU2298414C2 (ru) 2007-05-10
MXPA04001612A (es) 2004-07-08
JPWO2003015810A1 (ja) 2004-12-02
NO331682B1 (no) 2012-02-20
PL368708A1 (en) 2005-04-04
PT1426054E (pt) 2011-12-06
HU229521B1 (hu) 2014-01-28
ES2371630T3 (es) 2012-01-05
US8470783B2 (en) 2013-06-25
EP1426054B1 (en) 2011-09-28

Similar Documents

Publication Publication Date Title
NO20040731L (no) Medisinsk bruk av histon-deacetylase inhibitor og fremgangsmate og evaluering av dens antitumor-virkning.
McAdam et al. Oxidative stress–induced protein damage inhibits DNA repair and determines mutation risk and therapeutic efficacy
Nordal et al. Treatment of vitiligo with narrowband‐UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double‐blind comparative study
NO20013115L (no) En kombinasjon av FBPase inhibitorer og insulinsensibilisatorer for behandling av diabetes
NZ593388A (en) Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
JP2004527531A5 (no)
HK1089964A1 (en) Medical use of inhibitors of glutaminyl and glutamate cyclases
WO2004064727A3 (en) Method of cancer treatment using hdac inhibitors
TR200201246T2 (tr) Hidroksieikosatetraenoik asit türevlerini ihtiva eden bileşimler ve göz kuruması bozukluklarının iyileştirilmesinde kullanım yöntemleri
Stefanaki et al. Topical tacrolimus 0.1% ointment in the treatment of localized scleroderma. An open label clinical and histological study
Durigan et al. Neuromuscular electrical stimulation alters gene expression and delays quadriceps muscle atrophy of rats after anterior cruciate ligament transection
NO20033665D0 (no) Azoler som malonyl-CoA-dekarboksylaseinhibitorer som er anvendbare som metaboliske modulatorer
Gilberto de Castro et al. Evaluation, prevention and management of radiotherapy-induced xerostomia in head and neck cancer patients
WO2006094068A3 (en) Hdac inhibitors that promote brm expression and brm related diagnostics
Jørgensen et al. Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma
BRPI0809300A2 (pt) Compostos de carboxilato de metal nobre cataliticamente de elevada eficácia de ir, ru, rh, pd, pt e au
DK1611252T3 (da) In vitro-fremgangsmåde til påvisning af overgangscelle-karcinom i blæren
FR2840923B1 (fr) Agent anti-resistance a l'oxaliplatine
Somanath et al. Novel irreversible menin inhibitor, BMF-219, shows potent single agent activity in clinically relevant DLBCL cells
WO2005013802A3 (en) Trefoil factor 3 (tff3) as a target for anti-cancer therapy
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
Codilupi et al. CRL4 ubiquitin ligase stimulates Fanconi anemia pathway-induced single-stranded DNA-RPA signaling
BRPI0418022A (pt) biomarcadores para sensibilidade de doenças proliferativas a inibidores de mtor
BRPI0512342A (pt) métodos para aumento ósseo
WO2003079748A3 (en) Potentiation of cancer therapies by znf217 inhibition

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: PLOUGMANN 6 VINGTOFT POSTBOKS 1003 SENTRUM OSLO, 0

MM1K Lapsed by not paying the annual fees